Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 20:04:28 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Initiator Pharma Q4 report - Crucial year awaits

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Initiator Pharma Q4 report - Crucial year awaits

2023-02-17 11:25:00

Redeye provides a research update following the Q4 report published by Initiator Pharma earlier today. We make some slight adjustments to our estimates for operational expenditures, investments, net sales and estimated time plan for the projects IPED2015 and IP2018 following delays in patient recruitment. Accordingly, we update our fair value range with a revised base case valuation of SEK13.5 (SEK14) as we continue to see substantial upside potential in the stock.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/